| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF13 |
| Uniprot No | Q92913 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-245aa |
| 氨基酸序列 | MAAAIASSLI RQKRQARERE KSNACKCVSS PSKGKTSCDK NKLNVFSRVK LFGSKKRRRR RPEPQLKGIV TKLYSRQGYH LQLQADGTID GTKDEDSTYT LFNLIPVGLR VVAIQGVQTK LYLAMNSEGY LYTSELFTPE CKFKESVFEN YYVTYSSMIY RQQQSGRGWY LGLNKEGEIM KGNHVKKNKP AAHFLPKPLK VAMYKEPSLH DLTEFSRSGS GTPTKSRSVS GVLNGGKSMS HNEST |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于FGF13重组蛋白的文献概览(信息基于近期研究整理)：
1. **文献名称**: *"FGF13 regulates cerebellar granule cell development"*
**作者**: Wang Y, et al.
**摘要**: 研究利用重组FGF13蛋白在小鼠模型中揭示其通过调节微管稳定性促进小脑颗粒神经元迁移和突触形成的作用机制。
2. **文献名称**: *"Structural basis for fibroblast growth factor 13 mediated voltage-gated sodium channel modulation"*
**作者**: Parker JR, et al.
**摘要**: 通过体外重组FGF13蛋白的晶体结构解析，阐明其与电压门控钠通道(Nav1.6)的互作界面，为癫痫相关突变研究提供分子基础。
3. **文献名称**: *"FGF13 deficiency leads to abnormal cardiac electrophysiology and human disease modeling"*
**作者**: Li X, et al.
**摘要**: 利用重组FGF13蛋白回补实验，验证其在心肌细胞动作电位调控中的关键作用，与人类Brugada综合征表型相关。
4. **文献名称**: *"Recombinant FGF13 suppresses tumor growth via non-canonical signaling in colorectal cancer"*
**作者**: Chen H, et al.
**摘要**: 体外实验表明，外源性重组FGF13通过激活p38/MAPK通路抑制结直肠癌细胞增殖，提示其作为潜在肿瘤抑制因子的新功能。
注：以上内容为模拟示例，实际文献需通过PubMed/Google Scholar检索关键词“FGF13 recombinant”获取最新研究。
**Background of FGF13 Recombinant Protein**
Fibroblast Growth Factor 13 (FGF13), a member of the FGF family, belongs to the FGF homologous factor (FHF) subfamily (FGF11-FGF14). Unlike canonical FGFs, FHFs lack secretory signals and bind intracellular targets rather than FGF receptors. FGF13 is widely expressed in neural tissues, where it plays critical roles in neuronal development, ion channel regulation, and synaptic function. It stabilizes voltage-gated sodium channels (Nav) at axon initial segments and nodes of Ranvier, ensuring proper action potential initiation and propagation. Dysregulation of FGF13 is linked to neurodevelopmental disorders, including X-linked intellectual disability, epilepsy, and autism spectrum disorders.
Recombinant FGF13 protein is engineered using expression systems like *E. coli* or mammalian cells to produce functional, purified protein for research. Its production involves cloning the FGF13 gene into vectors, optimizing expression conditions, and employing chromatography techniques (e.g., affinity, ion-exchange) for purification. Quality control includes SDS-PAGE, Western blotting, and functional assays to confirm bioactivity.
In research, recombinant FGF13 aids in studying neuronal excitability, channelopathies, and disease mechanisms. It also serves as a tool for exploring FGF13's non-neuronal roles, such as in cardiac function or cancer progression, where aberrant expression may influence cell migration or survival. Despite therapeutic potential, challenges remain in delivering intracellular FGF13 effectively *in vivo*. Ongoing studies aim to clarify its signaling networks and develop targeted interventions for FGF13-associated pathologies.
×
